Drug resistance analysis of influenza virus to neuraminidase inhibitor from 2018 to 2019 in Hebei Province

JIANG Cai-xiao; HAN Guang-yue; LI Yan; LIU Yan-fang; LIU Lan-fen; QI Shun-xiang

doi:10.16462/j.cnki.zhjbkz.2020.02.021

Volume 24 Issue 2

Feb. 2020

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2020 > 24(2): 233-236

JIANG Cai-xiao, HAN Guang-yue, LI Yan, LIU Yan-fang, LIU Lan-fen, QI Shun-xiang. Drug resistance analysis of influenza virus to neuraminidase inhibitor from 2018 to 2019 in Hebei Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(2): 233-236. doi: 10.16462/j.cnki.zhjbkz.2020.02.021

Citation:

JIANG Cai-xiao, HAN Guang-yue, LI Yan, LIU Yan-fang, LIU Lan-fen, QI Shun-xiang. Drug resistance analysis of influenza virus to neuraminidase inhibitor from 2018 to 2019 in Hebei Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(2): 233-236. doi: 10.16462/j.cnki.zhjbkz.2020.02.021

Citation:

JIANG Cai-xiao, HAN Guang-yue, LI Yan, LIU Yan-fang, LIU Lan-fen, QI Shun-xiang. Drug resistance analysis of influenza virus to neuraminidase inhibitor from 2018 to 2019 in Hebei Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(2): 233-236. doi: 10.16462/j.cnki.zhjbkz.2020.02.021

PDF( 643 KB)

Drug resistance analysis of influenza virus to neuraminidase inhibitor from 2018 to 2019 in Hebei Province

doi: 10.16462/j.cnki.zhjbkz.2020.02.021

Institute of Prevention and Treatment for Viral Diseases, Hebei Center for Disease Control and Prevention, Shijiazhuang 050021, China

Funds: Hebei Medical Scientific Research Project of 2019(20190142)

More Information

Corresponding author: QI Shun-xiang, E-mail:hbcdc999@126.com
Received Date: 2019-09-11
Rev Recd Date: 2019-12-01
Publish Date: 2020-02-10

Abstract

Abstract

Objective To analyze the resistance of influenza virus to neuraminidase inhibitors(NAI) in Hebei province during 2018-2019. Methods Virus were collected from the Hebei Influenza Surveillance Network during 2018-2019. A total of 36 confirmed influenza viruses(with 25 H1 pdm09 and 11 H3 N2) were selected to test resistance to oseltamivir and zanamivi with fluorescence(FL). Results All 36 influenza viruses tested were sensitive to oseltamivir and zanamivir. The median half maximal inhibitory concentration(IC₅₀) for oseltamivir of H1 pdm09 and H3 N2 were of 0.50 nM(range 0.07-1.14 nM) and 0.25 nM(range 0.09-0.69 nM) respectively, while 0.29 nM(range 0.09-0.85 nM) and 0.87(range 0.17-1.81 nM) for zanamivir, all were within 10 fold IC₅₀ of the reference virus(corresponding type). Conclusion All the tested influenza strains isolated in Hebei province during 2018-2019 were sensitive to NAI.
- Influenza virus,
- Neuraminidase inhibitor,
- Resistance

FullText(HTML)

References(15)

References

[1]	李兰娟, 任红.传染病学[M].第8版.北京: 人民卫生出版社, 2013: 55. Li LJ, Ren H. Infectious Diseases[M]. 8th ed. Beijing: People's Medical Publishing House, 2013: 55.
[2]	邢晓会, 赵翔, 李希妍, 等.全球B型流感病毒耐药相关突变株NA和HA序列特征分析[J].中国人畜共患病学报, 2013, 29(10): 946-950. DOI: 10.3969/cjz.j.issn.1002-2694.2013.10.002. Xing XH, Zhao X, Li XY, et al. Characterization of the hemagglutinin and neuraminidase of global influenza B virus with drug-resistance[J]. Chin J of Zoo, 2013, 29(10): 946-950. DOI: 10.3969/cjz.j.issn.1002-2694.2013.10.002.
[3]	赵升, 僧明华, 吕宛玉, 等. 2017-2018年河南省流感病毒对神经氨酸酶抑制剂药物的耐药性研究[J].中华疾病控制杂志, 2019, 23(3): 259-262. DOI: 10.16462/j.cnki.zhjbkz.2019.03.003. Zhao S, Seng MH, Lu WY, et al. Resistance of influenza virus in Henan Province to neuraminidase inhibitor from 2017 to 2018[J]. Chin J Dis Control Prev, 2019, 23(3): 259-262, 288. DOI: 10.16462/j.cnki.zhjbkz.2019.03.003.
[4]	Nguyen HT, Sheu TG, Mishin VP, et al. Assessment of pandemic and seasonal influenza A(H1N1)virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays[J]. Antimicrob Agents Chemother, 2010, 54(9): 3671-3677. DOI: 10.1128/AAC.00581-10.
[5]	Okomo-Adhiambo M, Sleeman K, Ballenger K, et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective[J]. Viruses, 2010, 2(10): 2269-2289. DOI: 10.3390/v2102269.
[6]	中国国家流感中心.全国流感监测技术指南(2017年版). [EB/OL]. (2017-09-30)[2019-12-01]. http://www.chinaivdc.cn/cnic/zyzx/jcfa/201709/t20170930_153976.htm. Chinese National Influenza Center.National technical guidelines for influenza surveillance (2017edition).[EB/OL].(2017-09-30)[2019-12-01].http://www.chinaivdc.cn/cnic/zyzx/jcfa/201709/t20170930_153976.htm.
[7]	Nitsch-Osuch A, Brydak LB. Influenza viruses resistant to neuraminidase inhibitors[J]. Acta Biochim Pol, 2014, 61(3): 505-508.
[8]	Matrosovich MN, Matrosovich TY, Gray T, et al. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium[J]. J Virol, 2004, 78(22): 12665-12667. DOI: 10.1128/JVI.78.22.12665-12667.2004.
[9]	Yang X, Steukers L, Forier K, et al. A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus[J]. PLoS One, 2014, 9(10): e110026. DOI: 10.1371/journal.pone.0110026.
[10]	Du R, Cui Q, Rong L. Competitive cooperation of hemagglutinin and neuraminidase during influenza A virus entry[J]. Viruses, 2019, 11(5). DOI: 10.3390/v11050458.
[11]	Hurt AC, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015[J]. Antiviral Res, 2016, 132: 178-185. DOI: 10.1016/j.antiviral.2016.06.001.
[12]	陈寅, 茅海燕, 周敏, 等.浙江省近年来甲型H1N1流感病毒神经氨酸酶基因序列分析[J].疾病预测, 2013, 28(10): 811-814. DOI: 10.3784/j.issn.1003-9961.2013.10.007. Chen Y, Mao HY, Zhou M, et al. Sequence analysis of neuraminidase gene of influenza A(H1N1)pdm09 viruses in Zhejiang Province[J]. Disease Surveillance, 2013, 28(10): 811-814. DOI: 10.3784/j.issn.1003-9961.2013.10.007.
[13]	李娟, 赵晓南, 曹艺会, 等.云南省2009-2014年甲型H1N1流感病毒HA及NA基因特征分析[J].病毒学报, 2015, 31(6): 674-678. DOI: 10.13242/j.cnki.bingduxuebao.002829. Li J, Zhao XN, Cao YH, et al. Characterization of the hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 virus from 2009 to 2014 in Yunnan[J]. Chin J of Viro, 2015, 31(6): 674-678. DOI: 10.13242/j.cnki.bingduxuebao.002829.
[14]	谢剑峰, 张炎华, 赵琳, 等.一株达菲耐药的甲型H1N1流感病毒全基因特征分析[J].中国微生态学杂志, 2016, 28(8): 884-888. DOI: 10.13381/j.cnki.cjm.201608004. Xie JF, Zhang YH, Zhao L, et al. Characteristics of complete genome of an Oseltamivir-resistant influenza A(H1N1)pdm09 virus[J]. Chin J Microecol, 2016, 28(8): 884-888. DOI: 10.13381/j.cnki.cjm.201608004.
[15]	刘瑞弘, 文奇, 付倩, 等.新余市甲型H1N1流感病毒H275Y突变监测[J].实验与检验医学, 2018, 36(4): 472-474. DOI: 10.3969/j.issn.1674-1129.2018.04.003. Liu RH, Wen Q, Fu Q, et al. Surveillance of influenza A(H1N1)pdm09 virus with H275Y mutation in Xinyu[J]. Experimental and Laboratory Medicine, 2018, 36(4): 472-474. DOI: 10.3969/j.issn.1674-1129.2018.04.003.